1. Scrip
  2. >>Business
  3. >>Strategy

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

 
• By Sten Stovall

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Fossil fuel
Ipsen's Disease Areas Are Oncology, Neuroscience and Rare Diseases • Source: Shutterstock

Ipsen's American CEO David Meek says he's adequately funded to transform the French pharmaceutical group through R&D and M&A, and make good on its aim to launch at least one new drug or new valuable indication every year going forward.

In an interview with Scrip, the former US army officer also rejected concerns over the pharma's cancer drug Cabometyx (cabozantinib) being possibly displaced by novel immuno-oncology [IO] medicines, voicing his

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.